Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 14/20 | 0.39 |
| ▸ | GCGR | P47871 | 3/20 | 0.38 |
| ▸ | GLP1R | P43220 | 1/20 | 0.38 |
| ▸ | GIPR | P48546 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.32 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.32 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.32 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.32 |
| ▸ | MAP3K2 | Q9Y2U5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719688 | 0.86 | GCGR (0.47) | GCGGCGRGLP1RGIPRCNR1 | |
| SCHEMBL717433 | 0.76 | GCG (0.47) | GCGGCGRGLP1RGIPRCYP2D6 | |
| SCHEMBL720161 | 0.75 | P2RX7 (0.38) | GCG | |
| SCHEMBL720578 | 0.73 | PDE7A (0.33) | — | |
| SCHEMBL13069224 | 0.72 | GCG (0.44) | GCGGCGRGLP1RGIPRCYP2D6 | |
| SCHEMBL2669985 | 0.69 | GCGR (0.47) | GCGGCGRGLP1RGIPR | |
| SCHEMBL716763 | 0.68 | GCG (0.58) | GCGGCGRGLP1RGIPR | |
| SCHEMBL721236 | 0.68 | GCG (0.48) | GCGGCGRGLP1RGIPR | |
| SCHEMBL718932 | 0.68 | GCGR (0.49) | GCGGCGRGLP1RGIPR | |
| SCHEMBL717180 | 0.67 | GCG (0.43) | GCGGCGRGLP1RGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | GCG 35/4885GCGR 90/4885GLP1R 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.